6-bromo-1-(p-tolyl)hexan-1-one | 188973-49-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-bromo-1-(p-tolyl)hexan-1-one
• 英文别名: 6-Bromo-1-(4-methylphenyl)-1-hexanone；6-bromo-1-(4-methylphenyl)hexan-1-one
• CAS: 188973-49-1
• 化学式: C₁₃H₁₇BrO
• 分子量: 269.181
• InChiKey: IPKFISBDPLHZCI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6-bromo-1-(p-tolyl)hexan-1-one 在 三乙基硅烷 作用下， 反应 0.67h， 生成 6-(4-methylphenyl)-1-bromohexane
  参考文献：
  名称：

  Synthesis of neuroprotective cyclopentenone prostaglandin analogs: Suppression of manganese-induced apoptosis of PC12 cells

  摘要：

  The synthesis and evaluation for anti- and proapoptotic properties of cyclopenterione prostaglandin analogs are described. Novel J-type analogs of NEPP11 with a cross-conjugated cyclopentadienone moiety and a lipophilic omega-side chain suppressed manganese ion-induced apoptosis of PC12 cells at comparable levels to NEPP11, while monoenone derivatives were inactive. The proapoptotic activities of J-type analogs were much lower than that of NEPP11. Natural 15-deoxy-Delta(12,14)-PGJ(2) and Delta(7)-PGA(1) methyl ester were highly toxic, inducing apoptosis at lower concentrations. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.12.004
• 作为产物：
  描述：

  1-(对甲苯基)环己醇 在 碘苯二乙酸 、 sodium bromide 作用下， 以 乙腈 为溶剂， 反应 10.0h， 以55%的产率得到6-bromo-1-(p-tolyl)hexan-1-one
  参考文献：
  名称：

  通过β-烷氧基自由基的分裂，使未应变的环烷醇开环碘化和溴化。

  摘要：

  在可见光照射下，开发了未应变的环烷醇与NaI或NaBr和PhI（OAc）2的开环碘化或溴化反应。在该方案中，通过生成三碘化物（I3-）来调节I2的浓度，从而显着避免了不良的副反应。该反应在温和的条件下进行并且具有广泛的底物范围，因此提供了用于获得ω-碘或ω-溴代酮的实用方法。

  DOI：

  10.1039/d0cc01720e

文献信息

• Palladium-Catalyzed Room-Temperature Acylative Suzuki Coupling of High-Order Aryl Borons with Carboxylic Acids
  作者：Shufen Si、Chen Wang、Nan Zhang、Gang Zou

  DOI：10.1021/acs.joc.6b00421

  日期：2016.5.20

  Pd(OAc)2/PPh3-catalyzed acylative Suzuki coupling of carboxylic acids with diarylborinic acids or tetraarylboronates for practical and efficient synthesis of sterically undemanding aryl ketones at room temperature. More than just cost-effective alternatives to aryl boronic acids, diarylborinic acids and tetraarylboronates displayed higher reactivity in the acylative Suzuki coupling. A variety of alkyl aryl

  该说明描述了二碳酸二甲酯辅助的Pd（OAc）2 / PPh 3催化的羧酸与二芳基硼酸或四芳基硼酸酯的酰基Suzuki偶联反应，可在室温下实际有效地合成空间上不需要的芳基酮。芳基硼酸，二芳基硼酸和四芳基硼酸酯的不仅仅是成本有效的替代品，在酰基Suzuki偶联中显示出更高的反应性。各种烷基芳基酮，包括带有羟基，溴基或羰基的烷基芳基酮，都可以以中等至极好的收率容易地获得。
• Benzoic acid compounds and use thereof as medicaments
  申请人：Yoshitomi Pharmaceutical Industries, Ltd.

  公开号：US05864039A1

  公开（公告）日：1999-01-26

  Benzoic acid compounds of the formula ##STR1## wherein each symbol is as defined in the specification, optical isomers thereof and pharmaceutically acceptable salts thereof; pharmaceutical composition comprising this compound and pharmaceutically acceptable additive; and serotonin 4 receptor agonists, gastrointestinal prokinetic agents and therapeutic agents for various gastrointestinal diseases, which comprise this compound as active ingredient. The compounds of the present invention have high and selective affinity for serotonin 4 receptor, and show agonistic effects thereon. Accordingly, they are useful medications for the prophylaxis and treatment of various gastrointestinal diseases, central nervous disorders, cardiac function disorders, urinary diseases, and the like, as well as useful anti-nociceptors for analgesic use which increase threshold of pain.

  苯甲酸化合物的化学式为##STR1##，其中每个符号如规范中定义，其光学异构体及其药用可接受盐；包括该化合物和药用可接受添加剂的药物组合物；以及将该化合物作为活性成分的5-羟色胺4受体激动剂、胃肠促动力剂和用于各种胃肠疾病的治疗剂。本发明的化合物具有对5-羟色胺4受体的高度和选择性亲和力，并显示出激动效应。因此，它们可用于预防和治疗各种胃肠疾病、中枢神经障碍、心脏功能障碍、泌尿系统疾病等，同时还可用作提高疼痛阈值的镇痛用途的有用抗痛觉剂。
• Identification of Terfenadine as an Inhibitor of Human CD81-Receptor HCV-E2 Interaction: Synthesis and Structure Optimization
  作者：Marcel Holzer、Sigrid Ziegler、Beatrice Albrecht、Bernd Kronenberger、Artur Kaul、Ralf Bartenschlager、Lars Kattner、Christian Klein、Rolf Hartmann

  DOI：10.3390/molecules13051081

  日期：——

  Terfenadine (4-[4-(hydroxydiphenylmethyl)-1-piperidyl]-1-(4-tert-butylphenyl)-butan-1-ol) was identified in a biological screening to be a moderate inhibitor (27% inhibition) of the CD81-LEL–HCV-E2 interaction. To increase the observed biologicalactivity, 63 terfenadine derivates were synthesized via microwave assisted nucleophilicsubstitution. The prepared compounds were tested for their inhibitory potency by means ofa fluorescence labeled antibody assay using HUH7.5 cells. Distinct structure-activityrelationships could be derived. Optimization was successful, leading to 3g, identfied as themost potent compound (69 % inhibition). Experiments with viral particles revealed thatthere might be additional HCV infection reducing mechanisms.

  特非那定（4-[4-（羟二苯甲基）-1-哌啶基]-1-（4-叔丁基苯基）-丁烷-1-醇）在生物筛选中被识别为中等抑制剂（抑制率为27%），针对CD81-LEL与HCV-E2的相互作用。为了提高观察到的生物活性，通过微波辅助亲核取代合成了63个特非那定衍生物。这些制备的化合物通过使用HUH7.5细胞的荧光标记抗体检测法测试了它们的抑制效力。可以得出明显的结构-活性关系。优化取得了成功，导致了3g的识别，这是最强效的化合物（抑制率为69%）。对病毒颗粒的实验揭示可能存在额外的降低HCV感染的机制。
• Ring-opening iodination and bromination of unstrained cycloalkanols through β-scission of alkoxy radicals
  作者：Jiang-Ling Shi、Yuankai Wang、Zixuan Wang、Bowen Dou、Jianbo Wang

  DOI：10.1039/d0cc01720e

  日期：——

  Ring-opening iodination or bromination of unstrained cycloalkanols with NaI or NaBr and PhI(OAc)2 under visible light irradiation is developed. In this protocol the concentration of I2 is modulated through the generation of triiodide (I3-), thus significantly avoiding undesired side reactions. The reaction is under mild conditions and has a wide substrate scope, thus providing a practically useful

  在可见光照射下，开发了未应变的环烷醇与NaI或NaBr和PhI（OAc）2的开环碘化或溴化反应。在该方案中，通过生成三碘化物（I3-）来调节I2的浓度，从而显着避免了不良的副反应。该反应在温和的条件下进行并且具有广泛的底物范围，因此提供了用于获得ω-碘或ω-溴代酮的实用方法。
• Synthesis and pharmacological properties of benzamide derivatives as selective serotonin 4 receptor agonists
  作者：Shuji Sonda、Kenichi Katayama、Toshio Kawahara、Noriko Sato、Kiyoshi Asano

  DOI：10.1016/j.bmc.2004.02.036

  日期：2004.5

  selective 5-HT4 receptor agonist offering potential as a novel prokinetic with reduced side effects derived from 5-HT3- and dopamine D2 receptor-binding affinity. In the oral route of administration, this compound enhanced gastric emptying and defecation in mice, and has a possibility as a prokinetic agent, which is effective on both the upper and the lower gastrointestinal tract.

  合成了一系列在哌啶环的1-位具有极性取代基的4-氨基-5-氯-2-甲氧基-N-（哌啶-4-基甲基）苯甲酰胺，并评估了其对胃肠动力的影响。苯甲酰基，苯磺酰基和苄基磺酰基衍生物加速胃排空并增加排便频率。其中一种是选择性的5-HT 4，即4-氨基-N- [1- [3- [苄基磺酰基）丙基]哌啶-4-基甲基] -5-氯-2-甲氧基苯甲酰胺（13a，Y-36912）。受体激动剂具有潜力，可作为一种新型的促运动药物，具有降低的由5-HT3-和多巴胺D2受体结合亲和力产生的副作用。在口服给药途径中，该化合物可增强小鼠的胃排空和排便能力，并有可能作为促运动剂，